Further , in a cohort study of patients with type 2 diabetes , pioglitazone therapy was associated with a statistically significant decrease in the risk of all-cause mortality .
Despite these beneficial effects , the meta- analysis showed that pioglitazone therapy had higher risks of heart failure , bone fractures , edema and weight gain .
The low-dose pioglitazone therapy may show the same degree of improvements in glucose and lipid metabolism , fatty liver , insulin resistance , and adiponectin as the st and ard- and high-dose pioglitazone therapy .
Furthermore , the low-dose pioglitazone therapy may also show less adverse effects on weight gain , edema and heart failure as compared with the st and ard- and high-dose pioglitazone therapy
Pioglitazone is one of thiazolidinedione derivatives , which stimulates nuclear peroxisome proliferator-activated receptor gamma and improves glucose and lipid metabolism and insulin sensitivity .
A recent systematic review and meta- analysis showed that pioglitazone therapy was associated with a lower risk of major adverse cardiovascular events in patients with pre-diabetes and diabetes .
Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus.
It is well known that pioglitazone , a potent thiazolidinedione , improves metabolic control . However , weight gain or peripheral edema may be of major clinical concern when using this agent . The purpose of our study was to prospect ively evaluate the effects of low-dose pioglitazone ( 7.5 mg/day ) on metabolic control , weight gain and the incidence of edema compared with a st and ard dose of pioglitazone ( 15.0 mg/day ) in patients with type 2 diabetes mellitus ( T2DM ) . Ninety-five Japanese female patients ( mean age 58.4 + /- 10.4 years ) with newly diagnosed T2DM were selected for this study . They were r and omly divided into the following 2 groups according to therapy regimens , and examined every month for 6 months after diagnosis . Group A consisted of 54 patients treated with low-dose pioglitazone orally ; Group B , the control-group , consisted of 41 patients treated with st and ard-dose pioglitazone orally . The incidence of peripheral edema was significantly much lower in group A ( 2/54 ) than in group B ( 11/41 ) ( p = 0.0014 ) . In addition , % change of body weight during the 6-month treatment in group A was significantly less than that in group B ( p < 0.0001 ) . On the other h and , the % change of biochemical parameters including HbA1c did not differ significantly between group A and group B , although glucose and lipid control significantly improved from baseline in both groups . Our results demonstrate the safety and efficacy of low-dose pioglitazone , suggesting that it could be another good choice of treatment for Japanese women with T2DM
Further , in a cohort study of patients with type 2 diabetes , pioglitazone therapy was associated with a statistically significant decrease in the risk of all-cause mortality .
Despite these beneficial effects , the meta- analysis showed that pioglitazone therapy had higher risks of heart failure , bone fractures , edema and weight gain .
The low-dose pioglitazone therapy may show the same degree of improvements in glucose and lipid metabolism , fatty liver , insulin resistance , and adiponectin as the st and ard- and high-dose pioglitazone therapy .
Furthermore , the low-dose pioglitazone therapy may also show less adverse effects on weight gain , edema and heart failure as compared with the st and ard- and high-dose pioglitazone therapy
Pioglitazone is one of thiazolidinedione derivatives , which stimulates nuclear peroxisome proliferator-activated receptor gamma and improves glucose and lipid metabolism and insulin sensitivity .
A recent systematic review and meta- analysis showed that pioglitazone therapy was associated with a lower risk of major adverse cardiovascular events in patients with pre-diabetes and diabetes .